慢性乙型肝炎抗病毒治疗的现状及进展课件.ppt

Primary endpoint was improvement in histology Secondary 终点 Change from baseline in HBV DNA by PCR assay HBeAg loss and seroconversion (in HBeAg+ study) Change from baseline in ALT and normalization Improvement in fibrosis Safety At one year in both eAg+ and eAg- patients adefovir resulted in significant improvements in liver histology compared to placebo With increasing treatment duration, ADV therapy increases or maintains improvement in Significant and sustained 血清 HBV DNA reductions and % patients with HBV DNA undetectable by PCR-based assay ALT reduction and normalization HBeAg loss and